Last reviewed · How we verify

diclofenac diethylamine, DDEA 2.32% gel

Novartis · Phase 3 active Small molecule

diclofenac diethylamine, DDEA 2.32% gel is a NSAID Small molecule drug developed by Novartis. It is currently in Phase 3 development for Treatment of osteoarthritis, Treatment of rheumatoid arthritis.

Diclofenac diethylamine works by inhibiting the enzyme cyclooxygenase (COX), which is involved in the production of prostaglandins, leading to a reduction in inflammation and pain.

Diclofenac diethylamine works by inhibiting the enzyme cyclooxygenase (COX), which is involved in the production of prostaglandins, leading to a reduction in inflammation and pain. Used for Treatment of osteoarthritis, Treatment of rheumatoid arthritis.

At a glance

Generic namediclofenac diethylamine, DDEA 2.32% gel
SponsorNovartis
Drug classNSAID
TargetCOX-2
ModalitySmall molecule
Therapeutic areaRheumatology
PhasePhase 3

Mechanism of action

Diclofenac diethylamine is a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits COX-2, an enzyme responsible for the production of prostaglandins, which are mediators of inflammation and pain. By inhibiting COX-2, diclofenac diethylamine reduces the production of prostaglandins, leading to a decrease in inflammation and pain. This mechanism of action is responsible for its analgesic, anti-inflammatory, and antipyretic effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about diclofenac diethylamine, DDEA 2.32% gel

What is diclofenac diethylamine, DDEA 2.32% gel?

diclofenac diethylamine, DDEA 2.32% gel is a NSAID drug developed by Novartis, indicated for Treatment of osteoarthritis, Treatment of rheumatoid arthritis.

How does diclofenac diethylamine, DDEA 2.32% gel work?

Diclofenac diethylamine works by inhibiting the enzyme cyclooxygenase (COX), which is involved in the production of prostaglandins, leading to a reduction in inflammation and pain.

What is diclofenac diethylamine, DDEA 2.32% gel used for?

diclofenac diethylamine, DDEA 2.32% gel is indicated for Treatment of osteoarthritis, Treatment of rheumatoid arthritis.

Who makes diclofenac diethylamine, DDEA 2.32% gel?

diclofenac diethylamine, DDEA 2.32% gel is developed by Novartis (see full Novartis pipeline at /company/novartis).

What drug class is diclofenac diethylamine, DDEA 2.32% gel in?

diclofenac diethylamine, DDEA 2.32% gel belongs to the NSAID class. See all NSAID drugs at /class/nsaid.

What development phase is diclofenac diethylamine, DDEA 2.32% gel in?

diclofenac diethylamine, DDEA 2.32% gel is in Phase 3.

What are the side effects of diclofenac diethylamine, DDEA 2.32% gel?

Common side effects of diclofenac diethylamine, DDEA 2.32% gel include Gastrointestinal upset, Renal impairment, Hypersensitivity reactions.

What does diclofenac diethylamine, DDEA 2.32% gel target?

diclofenac diethylamine, DDEA 2.32% gel targets COX-2 and is a NSAID.

Related